Passage Bio 3Q 2026: EPS ($1.47) — 10-Q Summary

Passage Bio reported no revenue and a narrowed net loss of $4.72M for 3Q 2026, with EPS at ($1.47). The company wound down gene therapy programs, completed workforce restructuring, and expects to close a merger in 4Q 2026. Cash reserves were $20.2M, potentially insufficient for 12 months of operations.

Original reporting
Published Nov 10, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 12:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Passage Bio 3Q 2026: EPS ($1.47) — 10-Q Summary — source image
Decision brief

The 30-second read

$PASGBearishLow
01

Why it matters

The 10‑Q reveals a significant net‑loss reduction but still a negative EPS, with cash insufficient for a full year of operations, suggesting heightened downside risk unless the merger proceeds smoothly.

02

Market read

First disclosure of Passage Bio's quarterly performance and merger status; relevant for biotech micro‑caps and merger‑play traders.

03

What to watch

Potential hidden cash from asset sales or partnership opportunities not disclosed in the filing.

Relevance 6/10Novelty 6/10Timing: post‑market filing

Background

Passage Bio is winding down its gene‑therapy programs and has approved a merger to address its cash constraints.

Company-level read

Ticker impact

$PASGBearishHigh confidence
Context

Passage Bio filed its 10-Q showing no revenue, a narrowed net loss and a 75% workforce reduction, plus a pending merger.

Expected impact

likely pressure as investors price in weak earnings and limited cash

Evidence & confidence

First report of the quarterly results with concrete loss figures and cash balance; micro‑cap stocks typically react sharply to such negative guidance.

Market effects

Highlights challenges in the gene‑therapy biotech sector and may pressure peer biotech stocks.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The merger could unlock value if the combined entity secures funding, offering a turnaround play.

Key entities

  • Passage Bio, Inc.

    Biotech firm reporting its Q3 2026 results and merger approval.

Related articles

$PASGMed

Passage Bio Received Notice of Noncompliance

Passage Bio received a noncompliance notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement, reporting only $50,000. The company expects its pending merger with Remix Therapeutics to resolve the issue, with shares expected to trade under the symbol RMTX post-merger.

$AZIOMedAI 8/10

Azio AI 3Q 2026: Revenue $1.87M, EPS ($0.34) — 10-Q Summary

Azio AI reported 3Q 2026 revenue of $1.87M, up 3.3% YoY, and a net loss of $0.34 per share, narrowed 9.7%. Sales were driven by medical supplies to a related party, while higher G&A costs, including a $860,428 stock-based compensation adjustment, offset gains from debt settlement. AI infrastructure segment generated no revenue.